Futibatinib (Lytgobi®) Adverse Effects and Supportive Care Management
About this PQI
The Fibroblast Growth Factor Receptor (FGFR) pathway plays a key role in multiple fundamental cellular processes. The FGFR inhibitor futibatinib (Lytgobi®) is approved for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.1 The FGFR inhibitor drug class carries specific adverse effect profiles and monitoring considerations. The purpose of this PQI is to outline adverse effects of futibatinib (Lytgobi®) and provide recommendations to educate, monitor, and support patients appropriately.
How to Use a Positive Quality Intervention (PQI)
Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.
Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.
Find a PQI